Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease (SATBRAD)
Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease
Sponsor: Chang Gung Memorial Hospital
Listed as NCT04824911, this PHASE2 trial focuses on Acute Stroke and Dual Antiplatelet Therapy and remains completed. Sponsored by Chang Gung Memorial Hospital, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE2
-
Sep 2022 — Oct 2023 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE2
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chang Gung Memorial Hospital
For direct contact, visit the study record on ClinicalTrials.gov .